Related Experiment Video
Updated: Aug 13, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Cytosolic perfluorocarbon delivery to platelets via albumin for antithrombotic therapy
Lifeng Luo1, Zhong Chen2, Tong Gong2
1State Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Sciences, Nanjing University, Nanjing 210093, China; Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210093, China.
Insights
This study introduces a novel antiplatelet therapy using nanoscale perfluorocarbon (PFC) delivered by albumin. This approach inhibits platelet function independently of integrin αIIbβ3, reducing bleeding risk in thrombosis models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Hematology
Background:
- Thrombosis poses a significant global health challenge.
- Current antiplatelet therapies targeting integrin αIIbβ3 carry a high risk of bleeding.
- A need exists for safer, effective antiplatelet strategies.
Purpose of the Study:
- To develop an integrin αIIbβ3-independent antiplatelet method.
- To investigate the potential of cytosolic delivery of nanoscale perfluorocarbon (PFC) via albumin carriers for antiplatelet therapy.
Main Methods:
- Albumin-mediated cytosolic delivery of nanoscale perfluorocarbon (PFC) to platelets.
- Assessment of PFC's impact on platelet cytoskeleton reorganization and activation.
- Evaluation of antiplatelet efficacy and bleeding risk in various thrombosis models.
Main Results:
- Denatured albumin effectively mediated cytosolic PFC delivery into platelets.
- Cytosolic PFC inhibited platelet function by impairing cytoskeleton reorganization without affecting integrin αIIbβ3.
- The developed method demonstrated significant antiplatelet effects with a reduced bleeding risk.
Conclusions:
- Cytosolic PFC delivery via albumin represents a promising, safe alternative antiplatelet strategy.
- This approach offers a novel therapeutic option for managing thrombosis.
- Further research into this integrin αIIbβ3-independent method is warranted.
Abstract:
Thrombosis is a major contributor to global disease burden. Antiplatelet therapy is the critical approach to prevent thrombosis by reducing platelet reactivity. However, classical antiplatelet strategies generally interfere with platelet integrin αIIbβ3-mediated platelet activation, thereby facing severe bleeding risk. To break the limitation, we described an integrin αIIbβ3-independent antiplatelet method by cytosolic delivery of nanoscale perfluorocarbon (PFC) to platelets via albumin carrier. Denatured albumin was found to build high affinity with platelets to mediate cytosolic PFC delivery. While, cytosolic PFC impaired cytoskeleton reorganization during platelet activation to inhibit relevant platelet functions, but avoided to interfere with integrin αIIbβ3. We proved that this αIIbβ3-indenpendent antiplatelet pattern showed potential antiplatelet effect with low bleeding risk to prevent thrombosis in various thrombosis models. Together, cytosolic PFC delivery via albumin is a promising antiplatelet approach, and will provide an alternative regimen for current antithrombotic therapy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...